Introduction
The term "miscarriage" is synonymous to spontaneous abortion and is often used with patients, because the word "abortion" is associated with elective termination.¹ Miscarriage or abortion is variably defined as the expulsion or extraction of a fetus (embryo) weighing less than 500 grams equivalent to approximately 20-22 weeks gestation or as termination before 24 weeks of gestation with no evidence of life.² Incomplete miscarriage is a type of miscarriage in which some, but not all of the products of conception have been passed. Retained products may be part of the fetus, placenta, or membranes. It can result from either spontaneous or induced pregnancy loss.³ Incomplete miscarriage continues to contribute to maternal morbidity and mortality in much of the developing world.⁴ The complications which arise from incomplete miscarriage are hemorrhage and infection which occur because of remained tissue of conception or instrumentation through the cervix.² So safe and effective treatment for incomplete miscarriage is an important way to reduce abortion related morbidity and mortality.³'⁴ Incomplete miscarriage can be treated with expectant management, or active management using medical or surgical methods.⁵ Medical treatment of incomplete miscarriage has been categorized as a non-invasive option as it avoids the risks of women morbidity for those undergoing surgical evacuation, and require few resources and has the potential to improve greatly women's access to appropriate and effective care at secondary and even primary health care facilities. It is suitable for women far from surgical care facilities,⁶ not wanting hospital admission or unfit for general anesthesia.⁵'⁶ Misoprostol is a synthetic prostaglandin E1 analogue indicated for prevention and treatment of gastric and duodenal ulcers resulting from long-term use of non-steroidal antiinflammatory drugs. It is available in tablets form 200 mcg and 100 mcg in the market since 1985 in more than 87 countries and can be administered by different routes; orally, vaginally, rectally, buccally and sublingually. It is cheap, easily available, can be stored at room temperature for up to three years without long term effects on the women's health.⁷ In addition, misoprostol like natural prostaglandin affects more than one tissue of the body, including the stomach lining and the smooth muscle of uterus and the cervix.⁸ Many studies have shown that the uterotonic and cervical ripening properties of misoprostol make it an accepted and widely used treatment for incomplete miscarriage.⁹ The more recent studies suggest sublingual route of misoprostol to be the most potent 10 , and quickest onset of action compared to the other routes of administration due to high vascularity of buccal cavity. It also avoids the first pass effect through the liver,⁹'¹¹ and painful vaginal administration and is more convenient to be taken and acceptable by women.¹² The aim of this study was to compare the efficacy, patients' acceptability and the side effects of sublingual administration of single dose of 400mcg with single dose of 600mcg of misoprostol in the treatment of first trimester incomplete miscarriage.
Methods
city, Kurdistan region, Iraq. Among patients who attended the out-patient clinic, 120 pregnant women were interviewed and included in this study after taking written consent. All patients were cases of first trimester incomplete miscarriage with gestational age ≤12 weeks from last menstrual period. They had uneventful history with normal general examination. Gynecological examination revealed enlarged uterus with vaginal bleeding, and dilatation of the internal cervical os. Hemoglobin, blood group and Rhesus factor were estimated for patients under study. The diagnosis of incomplete miscarriage was confirmed by ultrasound examination showing evidence of retained products of conception. Exclusion criteria included signs and symptoms of hemodynamic instability or shock, suspicion of ectopic pregnancy, signs of pelvic infection and/or sepsis, known allergy to misoprostol or other prostaglandins, and history or evidence of disorders that represent contra -indication to the use of misoprostol like severe pulmonary diseases as asthma, congenital or acquired heart diseases, hypertension, prolonged use of corticosteroid, sickle cell anemia and adrenal insufficiency.¹² These patients were divided randomly into two groups (60 patients for each group). The first group received a single dose of 400 microgram misoprostol sublingually (Misotac). The second group received a single dose of 600 microgram misoprostol sublingually. These patients were instructed to hold these tablets under the tongue for about 30 minutes and after that any remaining tablet fragments can be swallowed with water.¹³ Treatment success was defined as complete evacuation of the uterus without the need for surgical intervention. At the day 7 follow-up visits, the abortion status of each woman was assessed using clinical examination, including an interview, bimanual examination and ultrasound examination. Women with substantial retained products in the uterus on examination on study day 7 underwent surgical evacuation. 
Results
The characteristics of both groups were compared regarding maternal age, parity, previous miscarriage and previous caesarean section are shown in Table 1 .
The mean maternal age ± SD of the first group was 29.48 ± 5.803 years compared with the second group of 28.93 ± 5.301 years (P = 0.589). Eighteen patients (30%) in the first group and 9 patients (15%) in the second group had previous miscarriages, (P = 0.049). In the first group 10 patients (16%) had previous caesarean section compared with 8 patients (13%) in the second group, (P = 0.16). The distribution of gestational age in both study groups is shown in Table 2 . The gestational age of 32 patients (53.3%) in the first group ranged between 5-8weeks compared with 29 patients (48.3%) in the second group. The gestational age of 28 patients (46.7%) in first group ranged between 9-12 weeks compared with 31 patients (51.7%) in the second group. All these differences were statistically not significant. Table 4 shows the frequency of side effects in the two groups. Most side effects were more common in the Group 2 compared with Group 1 with only nausia and diarrhea showing a statistically significant difference (P = 0.032). The patients' acceptability in each study group is shown in Table 5 . The acceptability rate in the first group was 58 patients (96.7%) compared to 57 patients (95%) in the second group (P = 0.85), and the difference was statistically not significant. However, two patients (3.3%) in first group did not like to choose this method again in future if they were allowed to choose in comparison to three patients (5%) in the second group (P = 0.85). The World Health Organization estimates that maternal mortality from abortionrelated complications accounts for 13% of all maternal deaths. Acute and long-term morbidities can include sepsis, hemorrhage and intra-abdominal injuries, while the resulting economic and emotional burden on families and communities is substantial.¹³'¹⁴ Post-abortion care, a term commonly used by international reproductive health community refers to a specific set of services for women experiencing problems from all types of spontaneous or induced abortion.⁶ Post-abortion care programs have recommended surgical methods for treatment of incomplete miscarriage, it works very well and provides a highly effective means of uterine evacuation, but surgical techniques require sterilized equipment along with providers skilled in their use and increased risks associated with anesthesia and instrumentation of the uterus.¹⁵ Now post-abortion care programs recommended misoprostol for treatment of incomplete miscarriage since its safe, effective and acceptable nonsurgical method¹⁶'¹⁷ based on the studies which documented the ability of misoprostol to induce uterine contractions and soften the cervix to empty the uterus in cases of incomplete abortion and miscarriage in the first trimester,¹⁵ and use of misoprostol for medication-based post-abortion care services has the capacity to increase women's access to treatment of incomplete miscarriage and abortion and reduce the financial burden on the health-care system.¹⁸'¹⁹ The results of this study were encouraging that sublingual administration of single dose of 400 mcg or 600 mcg misoprostol alone for medical evacuation of incomplete miscarriage up to 12 weeks successfully evacuated the uterus for 90% and 91.7% of patients respectively and acceptability was 96.7% and 95% respectively and there was no significant difference in both groups, and no serious adverse events were experienced by the patients, and allows a significant proportion of women to avoid surgical intervention. No previous study was found to compare 400mcg versus 600mcg sublingual misoprostol and only few published studies using sublingual misoprostol in the treatment of first trimester incomplete miscarriage and abortion. A study by Diop et al compared the efficacy, safety and acceptability of single dose of 400 mcg sublingual misoprostol and single dose of 600 mcg oral misoprostol in 150 patients for management of first trimester incomplete miscarriage. They reported a high efficacy of single dose of 400 mcg sublingual misoprostol which was 91%, which is slightly higher than our result may be due to larger sample size, and acceptability rate was 97%. 20 Another comparable study done by Raghavan and Bynum included more than 200 women with first trimester incomplete miscarriage and they divided in to two groups, oral group received single dose of 600 mcg misoprostol and sublingual group received single dose of 400 mcg misoprostol. They found that sublingual group has same complete miscarriage rate compared with oral group with efficacy rate 90%, this finding matches with our result. 21 A study by Nevine et al from Egypt included 697 women with incomplete miscarriage and compared the safety, efficacy, and acceptability of single dose of 400 mcg sublingual misoprostol with that of manual vacuum aspiration. The result was high success rate in both study group, 98.3% for misoprostol group which is higher than our result and may be due to the larger sample size. Regarding the side effects, 4% of misoprostol group had vomiting, 33.9% had abdominal cramps and complications like heavy vaginal bleeding was reported in 3% of misoprostol users, and the acceptability was 97%. These findings matches with our results, but 40% of patients had nausea and 20% had chills which is higher than our results, which may be due to larger sample size. 22 This study agrees with a study done by Khadija et al
Discussion

